Drug Release and Stability Study of Innovated Losartan Potassium and Rosuvastatin Calcium Fixed-dose Combination Tablet


Cite item

Full Text

Abstract

Background:Patient adherence to therapy and compliance is always a challenge for care providers in the management of chronic disorders with multiple medications.

Objective:Our study focused on formulating concurrently prescribed ARB (Angiotensin Receptor Blocker), i.e., losartan potassium, and a cholesterol-lowering statin derivative, i.e., rosuvastatin calcium, in a fixed-dose combination tablet.

Methods:The drugs were selected based on the presence of synergism and variation in solubility characteristics. Trial batches with fixed concentrations of both active pharmaceutical ingredients (APIs) and varying quantities of different excipients were prepared by dry granulation technique and subjected to different quality control tests for tablets. Batch F5 was selected on the basis of in-process quality control data for the development of a drug release protocol. Experimental conditions were optimized. Based on the sink condition, phosphate buffer (pH 6.8) was selected as the dissolution medium. Simultaneous determination of both APIs in samples collected at predetermined time intervals was carried out using the RP-HPLC technique with acetonitrile, methanol, and water (20:25:55 v/v/v) as mobile phase.

Results:Complete dissolution of both APIs in the FDC tablet was achieved in 45 min in 900 mL of the selected medium. The in vitro drug release protocol was validated for accuracy and precision without interference with sample analysis.

Conclusion:In this study, a validated, accurate, and robust dissolution testing method was developed for the newly formulated FDC tablet.

About the authors

Mian Inaam Zeb

Department of Pharmacy, Abdul Wali Khan University

Email: info@benthamscience.net

Salimullah Khan

Department of Pharmacy, Abdul Wali Khan University

Author for correspondence.
Email: info@benthamscience.net

Farid Ataya

Department of Biochemistry, College of Science, King Saud University

Email: info@benthamscience.net

Gaber Batiha

Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University

Email: info@benthamscience.net

Hamdy Kashtoh

Department of Biotechnology, Yeungnam University

Email: info@benthamscience.net

Ajmal Khan

Natural and Medical Sciences Research Center, University of Nizwa

Author for correspondence.
Email: info@benthamscience.net

Ahmed Al-Harrasi

Natural and Medical Sciences Research Center, University of Nizwa

Author for correspondence.
Email: info@benthamscience.net

References

  1. Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: Application in standardised treatment regimens. Drugs 2003; 63(6): 535-53. doi: 10.2165/00003495-200363060-00002 PMID: 12656652
  2. Braga JU, Trajman A. Effectiveness of RHZE-FDC (fixed-dose combination) compared to RH-FDC + Z for tuberculosis treatment in Brazil: A cohort study. BMC Infect Dis 2015; 15(1): 81. doi: 10.1186/s12879-015-0820-4 PMID: 25879615
  3. Campbell NRC. A step in the global effort to control hypertension: Fixed dose combination antihypertensive drugs. J Clin Hypertens 2019; 21(9): 1426-8. doi: 10.1111/jch.13683 PMID: 31441988
  4. Mahfoud F, Kieble M, Enners S, et al. Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: An example of guideline inertia. Clin Res Cardiol 2023; 112(2): 197-202. doi: 10.1007/s00392-022-01993-5 PMID: 35220445
  5. Lauffenburger JC, Landon JE, Fischer MA. Effect of combination therapy on adherence among US patients initiating therapy for hypertension: A cohort study. J Gen Intern Med 2017; 32(6): 619-25. doi: 10.1007/s11606-016-3972-z PMID: 28050754
  6. Belsey JD. Optimizing adherence in hypertension: A comparison of outcomes and costs using single tablet regimens vs. individual component regimens. J Med Econ 2012; 15(5): 897-905. doi: 10.3111/13696998.2012.689792 PMID: 22548677
  7. Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. PLoS Med 2018; 15(6): e1002584. doi: 10.1371/journal.pmed.1002584 PMID: 29889841
  8. Shah J, Kotadiya R. A critical review on analytical methods for recently approved FDC drugs: Pregabalin and etoricoxib. Crit Rev Anal Chem 2022; 52(5): 1048-68. doi: 10.1080/10408347.2020.1855411 PMID: 33307732
  9. World Health Organization Model List of Essential Medicines. World Health Organization model list of essential medicines: 21st list 2019. 2019. Available from: https://apps.who.int/iris/handle/10665/325771
  10. Yi I, Lee JJ, Park JS, et al. Enhanced effect of losartan and rosuvastatin on neointima hyperplasia. Arch Pharm Res 2010; 33(4): 593-600. doi: 10.1007/s12272-010-0414-z PMID: 20422369
  11. Ashokraj Y, Daroi A. Discriminatory dissolution method development and validation of etoricoxib tablets. Diss tech 2016; 23: 30-4.
  12. Rosuvastatin Tablets 2018. Available from: https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/rosuvastatin-tabs-rb-notice.pdf (Accessed on: 2022 December).
  13. Kumar P, Ankalgi AD, Kaushal P, Ashawat MS. Method development and validation for multicomponent analysis of rosuvastatin calcium and losartan potassium in bulk drug by RP-HPLC. J Drug Deliv Ther 2020; 10(5-s): 76-84. doi: 10.22270/jddt.v10i5-s.4341
  14. National Formulary USP 38-NF 33. Paper presented at the Rockville MD: The United States pharmacopeial convention. 2015. Available from: https://www.uspnf.com/official-text/proposal-statuscommentary/usp-38-nf-33
  15. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Topic Q2 (R1) validation of analytical procedures: Text and methodology. 2005. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q2r1-validation-analytical-procedures-text-and-methodology-step-5-first-version_en.pdf
  16. Mitrevska I, Achkoska T, Brezovska K, Toshev K, Dimitrovska A, Ugarkovic S. Development and validation of discriminative dissolution method for metformin immediate-release film-coated tablets. J Anal Methods Chem 2019; 2019: 1-8. doi: 10.1155/2019/4296321 PMID: 31886020
  17. Vaghela B, Kayastha R, Bhatt N, Pathak N, Rathod D. Development and validation of dissolution procedures. J Appl Pharm Sci 2011; 01: 50-6.
  18. Polli JE, Rekhi GS, Shah VP. Methods to compare dissolution profiles. Drug Inf J 1996; 30(4): 1113-20. doi: 10.1177/009286159603000428
  19. Seburg RA, Ballard JM, Hwang TL, Sullivan CM. Photosensitized degradation of losartan potassium in an extemporaneous suspension formulation. J Pharm Biomed Anal 2006; 42(4): 411-22. doi: 10.1016/j.jpba.2006.04.030 PMID: 16787732
  20. Afkham S, Hanaee J, Zakariazadeh M, Fathi F, Shafiee S, Soltani S. Molecular mechanism and thermodynamic study of Rosuvastatin interaction with human serum albumin using a surface plasmon resonance method combined with a multi-spectroscopic, and molecular modeling approach. Eur J Pharm Sci 2022; 168: 106005. doi: 10.1016/j.ejps.2021.106005 PMID: 34688823
  21. Kumar R, Kumar R, Khursheed R, et al. Development and validation of RP-HPLC method for estimation of fisetin in rat plasma. S Afr J Bot 2021; 140: 284-9. doi: 10.1016/j.sajb.2020.05.010
  22. Pawar HA, Joshi PR. Development and validation of a discriminating in vitro dissolution method for oral formulations containing satranidazole. Int J Spectrosc 2014; 2014(Spec): 1-7. doi: 10.1155/2014/624635
  23. Moghbel A, Abbaspour H. Study of compressibility properties of yogurt powder in order to prepare a complementary formulation. Iran J Pharm Res 2013; 12(3): 231-7. PMID: 24250628

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers